Medical Cannabis Trial with THC and CBD Reduces Agitation in Advanced Dementia

Initial data from a medical cannabis trial presented in London demonstrates that a THC and CBD formulation significantly reduces agitation in patients with advanced dementia compared to placebo. Behavioral symptoms like agitation are among the most challenging aspects of advanced dementia care, often requiring pharmaceutical interventions with considerable side effects. This research suggests cannabinoid therapy may offer a promising alternative for managing neuropsychiatric symptoms in dementia patients. The findings represent an important step toward expanding treatment options for this vulnerable population, though further clinical trials are needed to confirm efficacy and establish optimal dosing protocols.